Purpose: To study the combination of 5FUDR, recombinant leukocyte interferon (IFN), and doxorubicin in patients with unresectable hepatocellular carcinoma. Methods: IFN was administered at a dose of 6 miu/m2 subcutaneously followed in 2 h by doxorubicin 20 mg/m2 intravenously. After doxorubicin, 5FUDR was given as a 24-h infusion at a starting dose of 80 mg/kg. The dose of IFN was escalated to three times a week if tolerated. Both doxorubicin and 5FUDR were administered once weekly. Results: There were 30 patients entered into the study. Among the 30 patients, there were two partial responses (7%) and one patient had stable disease. Toxicity was generally tolerable with fever, and chills, fatigue, and myelosuppression as the most common side effects. Conclusions: This chemotherapy combination was generally well tolerated, but has limited activity in unresectable, advanced hepatocellular carcinoma.
|Original language||English (US)|
|Number of pages||4|
|Journal||Journal of cancer research and clinical oncology|
|State||Published - Jan 1 2003|
- Hepatocellular carcinoma
ASJC Scopus subject areas
- Cancer Research